Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder

Tumor Biology

Volumn 37, Issue 7, 2016, Pages 9855-9863

  Candido, Saverio ^a   Di Maso, Matteo ^b   Serraino, Diego ^b   McCubrey, James A ^c   Bortolus, Roberto ^b   Zanin, Martina ^d   Battiston, Monica ^b   Salemi, Rossella ^a   Libra, Massimo ^a   Polesel, Jerry ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

^d S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Bladder cancer; Diagnosis; Matrix metalloproteinase (MMP); Neutrophil gelatinase associated lipocalin (NGAL)

Indexed keywords

GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; LCN2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER PATIENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DRINKING BEHAVIOR; ENZYME BINDING; ENZYME BLOOD LEVEL; ENZYMURIA; FEMALE; GELATINASE B BLOOD LEVEL; GELATINASE B URINE LEVEL; HISTOPATHOLOGY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN BLOOD LEVEL; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN URINE LEVEL; NON PAPILLARY BLADDER CANCER; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SMOKING; STANDARDIZATION; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; ADOLESCENT; CANCER GRADING; CANCER STAGING; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYMOLOGY; FOLLOW UP; MIDDLE AGED; PROGNOSIS; URINARY BLADDER NEOPLASMS; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOCALIN-2; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84955315695     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4872-x     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Almallah YZ, Rennie CD, Stone J, Lancashire MJR. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology. 2000;56:37–9.
3. Yerlikaya G, Laml T, Elenskaia K, Hanzal E, Kölbl H, Umek W. Pain perception during outpatient cystoscopy: a prospective controlled study. Eur J Obstet Gynecol. 2014;173:101–05.
4. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Compérat E, et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–53.
5. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, Shariat SF. Urinary markers for detection and surveillance of bladder cancer. Urol Oncol. 2014;32:222–9.
6. Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J, Cantley LG. Expression of neutrophil gelatinase- associated lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem. 2005;280:7875–82.
7. Bratt T. Lipocalins and cancer. Biochim Biophys Acta. 2000;1482:318–26.
8. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;276:37258–65.
9. Barresi V, Reggiani-Bonetti L, Di Gregorio C, Vitarelli E, Ponz De Leon M, Barresi G. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathol Res Pract. 2011;207:479–86.
10. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 2010;288:10–6.
11. Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, et al. Mulitplex protein signature for the detection of bladder cancer in voided urine samples. J Urol. 2013;190:2257–62.
12. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Nonivasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MPP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007;52:1388–97.
13. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with high stage and grade of bladder carcinoma. Urology. 2001;57:675–79.
14. Nutt JE, Durkan JK, Lunec J. Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int. 2003;91:99–104.
15. Fernández CA, Eszolek MF, Loughlin KR, Libertino JA, Summerhayes IC, Shuber AP. A novel approach to using matrix metalloproteinases for bladder cancer. J Urol. 2009;182:2188–94.
16. Ricci S, Bruzzese D, Di Carlo A. Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer. Oncol Lett. 2015;10:25272532.
17. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. 2008;108:389–97.
18. Coticchia CM, Curatolo AS, Zurakowski D, Yang J, Daniels KE, Matulonis UA, et al. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol. 2011;123:295–300.
19. Fernández CA, Yan L, Gwendolyn L, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005;11:5390–5.
20. Kubben FJGM, Sier CFM, Hawinkels LJAC, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 2007;43:1869–76.
21. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Wang Z, et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol. 2007;60:555–61.
22. Shimura T, Dagher A, Sachdev M, Ebi M, Yamada T, Yamada T, et al. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila). 2015. doi:10.1158/1940-6207.CAPR-14-0229.
23. Mbeunkui F, Johann Jr DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63:571–82.
24. Stemmer K, Perez-Tilve D, Ananthakrishnan G, Bort A, Seeley RJ, Tschöp MH, et al. High-fat-diet-induced obesity causes an inflammatory and tumor-promoting microenvironment in the rat kidney. Dis Model Mech. 2012;5:627–35.
25. Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Fitzgerald TL, Martelli AM, et al. Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochim Biophys Acta. 2016;1863:438–48.
26. Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget. 2014;30:1576–94.
27. Polesel J, Gheit T, Talamini R, Shahzad N, Lenardon O, Sylla B, et al. Urinary human polyomavirus and papilloma virus infection and bladder cancer risk. Br J Cancer. 2012;106:222–6.
28. D’Avanzo B, La Vecchia C, Katsouyanni K, Negri E, Trichopoulos D. Reliability of information on cigarette smoking and beverage consumption provided by hospital controls. Epidemiology. 1996;7:312–5.
29. 2 criteria. Stat Soft Newsletter. 1997;26:239–50.
30. Faraggi D, Reiser B. Estimation of the area under the ROC curve. Stat Med. 2002;21:3093–106.
31. Sier CFM, Casetta G, Verhijen JH, Tizzani A, Agape V, Kos J, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res. 2000;6:2333–40.
32. Di Carlo A. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumours. Oncol Lett. 2013;5:1677–81.
33. Larré S, Catto JWF, Cookson MS, Messing EM, Shariat SF, Soloway MS, et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013;63:1049–58.
34. Behrens T, Bonberg N, Casjens S, Pesch B, Brüning T. A practical guide to epidemiological practice and standards in the identification and validation of diagnostic markers using a bladder cancer example. Biochim Biophys Acta. 1844;2014:145–55.